More than half of adults with obesity stop using Wegovy within 1 year

More than half of adults who used once-weekly semaglutide for obesity treatment discontinued the drug after less than 1 year, according to data presented at the European Association for the Study of Diabetes annual meeting. In a population-based study conducted in Denmark, researchers assessed semaglutide (Wegovy, Novo Nordisk) use among adults without diabetes who began using the medication